You have read all your free articles, to continue reading subscribe to read the rest of this content.
Targovax has completed patient enrollment in the phase I trial with ONCOS-102 in combination with Keytruda in patients with advanced anti-PD1 checkpoint inhibitor (CPI) refractory melanoma. In this trial, ONCOS-102 immune activation is being tested in patients with advanced, unresectable melanomaAlready a subscriber Login You have read all your free…
AstraZeneca and MedImmune, have announced that the US Food and Drug Administration has granted Breakthrough Therapy designation (BTD) for durvalumab (MEDI4736), an investigational human monoclonal antibody directed against programmed death ligand-1 (PD-L1), for the treatment of patients with PD-L1 Already a subscriber Login You have read all your free articles, to…
The company announces that the dosing of patients in its first trial PP-CT01, studying the safety and tolerability of XEN-D0501 in patients with type 2 diabetes, was completed. XEN-D0501 is a highly selective and very potent TRPV1 antagonist, previously in development by Bayer Healthcare and XentAlready a subscriber Login You…
The company has completed a phase IIB randomized, double-blind, placebo-controlled trial in Finnish travellers going to Benin in West Africa. All participants have now been enrolled and the last travellers left Benin in March 2019. The last follow up visit was conducted just before Easter. In totAlready a subscriber Login…
